BPC-157: preclinical research, study endpoints and evidence limits
BPC-157 is a synthetic 15-amino-acid peptide studied in tissue and cellular-response models. The selected papers below examine tendon cells, receptor signalling and angiogenesis. Their preclinical findings do not establish healing or safety in people, or verify the contents of a research vial.
Tendon-cell migration is different from proliferation
Chang and colleagues’ 2011 study used rat Achilles tendon explants and cultured fibroblasts. It found increased cell outgrowth, migration and survival under oxidative stress. The same experiments did not find a direct increase in cell proliferation.
Changes in FAK and paxillin phosphorylation accompanied the migration findings. These are laboratory measurements of cellular behaviour and signalling, not measurements of repaired human tendons. An explant is tissue studied outside the animal; it should not be described as a clinical trial.
More receptor expression does not mean more growth hormone
In the 2014 rat tendon-fibroblast study, BPC-157 increased growth hormone receptor expression at the RNA and protein levels. Researchers then added growth hormone and measured proliferation-related responses and JAK2 signalling in the pretreated cells.
The experiment concerns how cultured cells responded to an added signal. It does not show that BPC-157 raises circulating growth hormone, and it does not measure human injury recovery. Keep receptor expression, hormone concentration and a clinical outcome as separate claims.
What the VEGFR2 and angiogenesis paper examined
Hsieh and colleagues’ 2017 paper combined endothelial-cell experiments, a chick chorioallantoic membrane assay and a rat hind-limb ischaemia model. It reported angiogenesis-related changes and blood-flow recovery in the rat model, together with VEGFR2-associated signalling measurements.
VEGFR2 is vascular endothelial growth factor receptor 2. The cultured-cell work reported increased receptor expression, without increased VEGF-A expression. A receptor, its ligand and an observed blood-vessel response are different endpoints. Human-derived endothelial cells remain an in-vitro model, not treated human participants.
Read the material, model and endpoint together
These are selected primary studies from 2011–2017, not a systematic review, a current clinical-trial inventory or a regulatory-status assessment. They illustrate distinct research questions; their results should not be combined into an assumed human benefit.
| Study and model | Measured question | Important limit |
|---|---|---|
| Chang et al., 2011 · rat explants and cells | Outgrowth, migration, stress survival and signalling. | Cell movement is not proof of whole-tendon recovery. |
| Chang et al., 2014 · rat tendon fibroblasts | Receptor expression and response to added growth hormone. | Does not measure circulating hormone or clinical recovery. |
| Hsieh et al., 2017 · cells, chick membrane and rats | Angiogenesis, VEGFR2 signalling and rat blood flow. | Does not establish efficacy or safety in people. |
A research paper and a batch report answer different questions
A literature reference explains an experiment. A COA records tests on an identified sample. Check the material name, sample identifier, method, units and measured results, then establish whether the report is linked to the relevant stock lot.
Identity, purity and quantity are separate questions. A suitable assay must support the particular claim being made; a purity result is not a clinical safety assessment. A matching compound name alone is insufficient to connect a published experiment or a laboratory sample to a current vial.
Use the listing to inspect the available documentation
The FSD BPC-157 product page and filtered COA library provide the available records for the selected listing. Check the original report and the stated stock-lot relationship rather than treating the presence of a report as a confirmed match.
FSD materials are for laboratory research, not for human or veterinary administration. This guide gives no human-use regimen and makes no claim that a catalogue product reproduces a published experimental result.
Common questions
Does BPC-157 tendon-cell research prove that it heals human injuries?
No. The cited tendon work used rat tissue and cultured cells. Those endpoints do not establish human healing, clinical effectiveness or safety.
Does the growth hormone receptor paper show increased growth hormone levels?
No. It measured receptor expression and cellular responses after growth hormone was added. It did not measure an increase in circulating growth hormone.
Is an experiment using human endothelial cells a human clinical trial?
No. The cited angiogenesis paper used human-derived cells in a laboratory alongside chick and rat models. It did not measure treatment outcomes in human participants.
Does a BPC-157 paper verify an FSD vial?
No. Published research and stock documentation are separate. Read the original laboratory report and confirm its sample-to-stock relationship for the material being assessed.
Sources & scope
These references explain analytical and research principles. They do not certify FSD BIO LABS or provide evidence about a particular FSD batch.
- BPC-157: rat tendon explants and fibroblast migration (2011) — Chang et al. · Journal of Applied Physiology
Primary rat-tissue and cultured-cell experiments. Distinguishes migration, stress survival and FAK–paxillin signalling from cell proliferation; not a clinical treatment trial. - BPC-157 and growth hormone receptor expression in tendon fibroblasts (2014) — Chang et al. · Molecules
Primary rat tendon-fibroblast study. Receptor expression and responses after added growth hormone do not establish increased circulating growth hormone or outcomes in people. - BPC-157: angiogenesis models and VEGFR2 signalling (2017) — Hsieh et al. · Journal of Molecular Medicine
Primary endothelial-cell, chick-membrane and rat hind-limb experiments. Pathway and blood-flow measurements remain preclinical evidence. - ICH Q2(R2): Validation of Analytical Procedures — FDA / ICH
Specificity, accuracy, precision, reportable range and the use of complementary analytical procedures; a method name alone does not establish fitness for a particular measurement. - ICH Q7: Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients — FDA / ICH
Sections 11.4 and 17 describe COA contents, original report references and batch traceability. Used as a documentation benchmark; it does not establish FSD's GMP status.